These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 37699634)
61. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial. Dickhoff C; Senan S; Schneiders FL; Veltman J; Hashemi S; Daniels JMA; Fransen M; Heineman DJ; Radonic T; van de Ven PM; Bartelink IH; Meijboom LJ; Garcia-Vallejo JJ; Oprea-Lager DE; de Gruijl TD; Bahce I BMC Cancer; 2020 Aug; 20(1):764. PubMed ID: 32795284 [TBL] [Abstract][Full Text] [Related]
62. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN). Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909 [TBL] [Abstract][Full Text] [Related]
63. Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. Wong SJ; Winter K; Meropol NJ; Anne PR; Kachnic L; Rashid A; Watson JC; Mitchell E; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1367-75. PubMed ID: 21775070 [TBL] [Abstract][Full Text] [Related]
64. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study. Czito BG; Deming DA; Jameson GS; Mulcahy MF; Vaghefi H; Dudley MW; Holen KD; DeLuca A; Mittapalli RK; Munasinghe W; He L; Zalcberg JR; Ngan SY; Komarnitsky P; Michael M Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):418-426. PubMed ID: 28497757 [TBL] [Abstract][Full Text] [Related]
65. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Akova M; Unal S Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629 [TBL] [Abstract][Full Text] [Related]
66. Short-course radiotherapy with consolidation chemotherapy versus conventionally fractionated long-course chemoradiotherapy for locally advanced rectal cancer: randomized clinical trial. Chakrabarti D; Rajan S; Akhtar N; Qayoom S; Gupta S; Verma M; Srivastava K; Kumar V; Bhatt MLB; Gupta R Br J Surg; 2021 May; 108(5):511-520. PubMed ID: 33724296 [TBL] [Abstract][Full Text] [Related]
67. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial. Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053 [TBL] [Abstract][Full Text] [Related]
68. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer. Kokka F; Bryant A; Brockbank E; Powell M; Oram D Cochrane Database Syst Rev; 2015 Apr; (4):CD010260. PubMed ID: 25847525 [TBL] [Abstract][Full Text] [Related]
69. Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial. Yuan JJ; Ding JW; Li JW; Hu RH; Gong D; Hu JL; Zhu KB; Liu Y; Ding YH; Wei JW; Zeng JL; Lu ZB; Yin WH; Ai SF; Zha GH; Zhang ZL; Zou R; Zeng L BMJ Open; 2022 Aug; 12(8):e051594. PubMed ID: 36008072 [TBL] [Abstract][Full Text] [Related]
70. Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial. Gerard JP; Barbet N; Schiappa R; Magné N; Martel I; Mineur L; Deberne M; Zilli T; Dhadda A; Myint AS; Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):356-367. PubMed ID: 36801007 [TBL] [Abstract][Full Text] [Related]
71. Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer. Araujo-Mino EP; Patt YZ; Murray-Krezan C; Hanson JA; Bansal P; Liem BJ; Rajput A; Fekrazad MH; Heywood G; Lee FC Oncologist; 2018 Jan; 23(1):2-e5. PubMed ID: 29158365 [TBL] [Abstract][Full Text] [Related]
72. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer--the RAPIDO trial. Nilsson PJ; van Etten B; Hospers GA; Påhlman L; van de Velde CJ; Beets-Tan RG; Blomqvist L; Beukema JC; Kapiteijn E; Marijnen CA; Nagtegaal ID; Wiggers T; Glimelius B BMC Cancer; 2013 Jun; 13():279. PubMed ID: 23742033 [TBL] [Abstract][Full Text] [Related]
73. Efficacy of Dose-Escalated Chemoradiation on Complete Tumor Response in Patients with Locally Advanced Rectal Cancer (RECTAL-BOOST): A Phase 2 Randomized Controlled Trial. Couwenberg AM; Burbach JPM; Berbee M; Lacle MM; Arensman R; Raicu MG; Wessels FJ; Verdult J; Roodhart J; Reerink O; Hoendervangers S; Buijsen J; Grabsch HI; Pronk A; Consten ECJ; Smits AB; Heikens JT; Appelt AL; van Grevenstein WMU; Verkooijen HM; Intven MPW Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):1008-1018. PubMed ID: 32565319 [TBL] [Abstract][Full Text] [Related]
74. Comparison of outcomes and side effects for neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation vs. chemoradiation alone in stage IIB-IVA cervical cancer: study protocol for a randomized controlled trial. Li J; Liu H; Li Y; Li J; Shen L; Long W; Yang C; Xu H; Xi W; Cai R; Feng W Trials; 2022 Jan; 23(1):29. PubMed ID: 35012634 [TBL] [Abstract][Full Text] [Related]
75. Pirfenidone for the prevention of radiation-induced lung injury in patients with locally advanced oesophageal squamous cell carcinoma: a protocol for a randomised controlled trial. Chen C; Zeng B; Xue D; Cao R; Liao S; Yang Y; Li Z; Kang M; Chen C; Xu B BMJ Open; 2022 Oct; 12(10):e060619. PubMed ID: 36302570 [TBL] [Abstract][Full Text] [Related]
76. Evaluating the efficacy and safety of neoadjuvant pembrolizumab in patients with stage I-III MMR-deficient colon cancer: a national, multicentre, prospective, single-arm, phase II study protocol. Justesen TF; Gögenur I; Tarpgaard LS; Pfeiffer P; Qvortrup C BMJ Open; 2023 Jun; 13(6):e073372. PubMed ID: 37349100 [TBL] [Abstract][Full Text] [Related]
77. Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer. Wang L; Li ZY; Li ZW; Li YH; Sun YS; Ji JF; Gu J; Cai Y Dis Colon Rectum; 2015 Feb; 58(2):186-92. PubMed ID: 25585076 [TBL] [Abstract][Full Text] [Related]
78. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Altorki NK; McGraw TE; Borczuk AC; Saxena A; Port JL; Stiles BM; Lee BE; Sanfilippo NJ; Scheff RJ; Pua BB; Gruden JF; Christos PJ; Spinelli C; Gakuria J; Uppal M; Binder B; Elemento O; Ballman KV; Formenti SC Lancet Oncol; 2021 Jun; 22(6):824-835. PubMed ID: 34015311 [TBL] [Abstract][Full Text] [Related]
79. Neoadjuvant treatment of sintilimab plus hypofractionated radiotherapy for MSI-H/dMMR rectal cancer: A prospective, multicenter, phase Ib study. Li X; Fang C; Wang X; Yu Y; Wang Z; Qiu M Cancer Med; 2022 Dec; 11(23):4405-4410. PubMed ID: 35352512 [TBL] [Abstract][Full Text] [Related]
80. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy]. Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]